RA
BPMC

Royce & Associates’s Blueprint Medicines BPMC Stock Holding History

Royce & Associates’s Portfolio BPMC Stock Details BPMC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-18,001
Closed -$1.59M – 794
2025
Q1 		$1.59M Buy
+18,001
New +$1.76M 0.02% 625

Other funds holding BPMC

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Royce & Associates's BPMC Position: Q2 2025 in Review

Royce & Associates sold out of Blueprint Medicines (BPMC) in Q2 2025, closing a stake of 18,001 shares — an estimated $1.59M sold.

Royce & Associates first reported a position in BPMC in Q1 2025 and held it in 1 quarter. The position peaked at $1.59M in Q1 2025. 355 funds tracked by Wall St. Rank hold BPMC as of Q2 2025.

  • Royce & Associates reported no remaining Blueprint Medicines position as of Q2 2025 after selling out during the quarter.
  • Royce & Associates sold 18,001 Blueprint Medicines shares in Q2 2025, an estimated $1.59M.
  • Royce & Associates first reported a position in Blueprint Medicines in Q1 2025 and held it in 1 quarter.
  • Royce & Associates's Blueprint Medicines position peaked at $1.59M in Q1 2025.
  • 355 funds tracked by Wall St. Rank held Blueprint Medicines as of Q2 2025.

Based on Royce & Associates's 13F filing for Q2 2025, filed 11 Aug 2025.